Everolimus (EVE) Safety Profile in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumours (NETs) from Daily Clinical Practice

#1417

Introduction: EVE has shown an overall favourable and well-characterized safety profile in randomized studies including advanced G1-G2 NETs. However, few data outside regulatory trials are available.

Aim(s): Evaluation of EVE tolerability according to prior therapies for pts with advanced NETs in the community setting.

Materials and methods: Retrospective analysis on pts with advanced G1-G2 NETs treated with EVE in 10 Spanish University hospitals between June-2009 and June-2015.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Carmona-Bayonas A

Authors: Carmona-Bayonas A, Jiménez-Munarriz B, Jimenez-Fonseca P, Custodio A, Alonso V,

Keywords: everolimus,tolerability,

To read the full abstract, please log into your ENETS Member account.